Study of Cushing's Syndrome Not Related to ACTH Production

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

18 participants

Study Classification

OBSERVATIONAL

Study Start Date

2000-09-30

Study Completion Date

2002-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to provide information about the cause of two unusual types of Cushing's syndrome and to evaluate quality of life before and after cure of the disease. In Cushing's syndrome, the adrenal glands produce too much of the hormone cortisol. This often causes weight gain, skin changes (bruising and stretch marks), and mood changes such as irritability, easy crying and depression. Adrenocorticotrophic hormone (ACTH) normally regulates cortisol production; when cortisol is low, ACTH rises, stimulating the adrenals to produce more cortisol, and when cortisol is high, ACTH levels fall. In two forms of Cushing's syndrome, however, the adrenal glands produce cortisol even when ACTH is low.

Patients 18 years of age and older with Cushing's syndrome not related to ACTH production may participate in this study. Candidates will be have a history and physical examination, electrocardiogram, urine, blood and saliva tests, and a computerized tomography (CT) scan of one or both adrenal glands. They will fill out questionnaires on their disease symptoms, quality of life, and on basic information about themselves, such as marital status, education level, place of residence, etc. Finally, they will have a corticotropin-releasing hormone (CRH) test to confirm that they have the form of Cushing's syndrome under study in this protocol. This test involves collecting blood samples at intervals before and after administration of sheep CRH to measure cortisol and ACTH levels.

Participants will undergo 3 to 7 days of testing to determine if their cortisol level rises after taking certain medicines or eating certain foods. These foods and medicines, chosen to mimic or stimulate substances already in the body, are: glucagon, ACTH, gonadotropin-releasing hormone, vasopressin, thyrotropin-releasing hormone, and a mixed meal consisting of a protein, carbohydrate and fat (usually chicken breast and a milkshake-like drink). Blood will be collected at intervals before and after taking the food or medicine to measure cortisol blood levels. Blood will also be collected while the patient is in a standing position and while lying in bed, because changes in posture can cause substances in the body to increase or decrease. Depending on the individual's response to these tests, additional tests may be done with insulin, glucose, luteinizing hormone and follicle-stimulating hormone.

Patients who do not respond to these substances will undergo adrenalectomy (surgery to remove one or both adrenal glands). This is standard treatment for this type of Cushing's syndrome. It is usually done by laparoscopy, in which air is injected into the abdomen through tubes inserted through a small incision, enabling the surgeon to see the organs and remove the gland. Part of the removed tissue will be examined to learn about what causes this type of Cushing's syndrome; it may also be used for genetic studies related to the disease. Patients will stay in the hospital for a week to 10 days for observation and treatment and then will be discharged to the care of their own doctor. They will continue to complete the quality of life questionnaire every 3 months for 2 years.

Patients with normal adrenal glands who are participating in National Cancer Institute studies and are scheduled for adrenalectomy as part of their standard treatment will also be recruited for this study to serve as controls. The patients will have a 24-hour urine collection, and part of the adrenal gland tissue removed for their treatment will be used for research purposes of this study, possibly including genetic study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Diagnostic Performance of Screening Tests for Cushing s Syndrome

NCT00361777

Cushing's Syndrome

COMPLETED

New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome

NCT00001849

Cushing Syndrome Endocrine Disease

COMPLETED PHASE2

Jugular Vein Sampling for Hormone Levels for the Diagnosis of Cushing Syndrome

NCT00001453

Cushing's Syndrome

COMPLETED

Saliva Cortisol Measurement as a Screening Test for Suspicious Cushings Syndrome in Children.

NCT02646553

Cushings Syndrome

UNKNOWN

Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism

NCT02001051

Subclinical Hypercortisolism Cushing Syndrome Adrenal Neoplasm

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In healthy individuals, ACTH is the major stimulus for cortisol production and cellular growth of the adrenal cortex. Normal or elevated ACTH levels can amplify this stimulus, leading to hypercortisolism and growth of the adrenal gland, a clinical condition recognized as Cushing's syndrome. However, some patients with hypercortisolism of Cushing's syndrome have suppressed rather than normal or high levels of ACTH. This pilot study seeks to better understand the apparently autonomous nature of hypercortisolism in two benign causes of Cushing's syndrome, adrenal adenomas and massive macronodular adrenal disease (MMAD).

Patients with low levels of ACTH and Cushing's syndrome will undergo routine tests to confirm that they have hypercortisolism, low ACTH, and adenoma or MMAD on CT scans. They will fill out a questionnaire about quality of life. They will also undergo 3-7 days of research testing with a variety of agents to investigate whether these agents increase cortisol. Following this, patients will be scheduled for adrenalectomy at the NIH. This is the standard treatment for these conditions. The abnormal tissue obtained at surgery will be used for laboratory studies to evaluate whether the same or other agents may be the cause of excess cortisol production.

After surgery, patients will be discharged to the care of their local health care provider, but will continue to fill out questionnaires on the quality of life for two years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cushing's Syndrome Healthy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

PATIENTS WITH NORMAL ADRENAL GLANDS:

Patients with normal adrenal glands will be recruited from those studied under NCI protocols.

They will not have taken suppressive doses of glucocorticoids for 12 months, and will not have any known adrenal pathology, either of the cortex or medulla.

They will not have Von-Hippel Lindau syndrome.

PATIENTS WITH ACTH-INDEPENDENT CUSHING'S SYNDROME:

Will be aged 18 or older;

Will have plasma ACTH levels of 10 pg/mL or less;

Will have an outside physician who will follow them after surgery.

Must not weigh greater than 380 pounds. These patients are unable to undergo CT scans.

Must not have a CT scan showing normal or atrophic bilateral adrenal glands.

Must not have a CRH test showing a response as defined above. The diagnosis of these patients will need further evaluation.

Must not have any condition that would preclude surgery, including advanced heart failure, significant coronary artery disease, severe pulmonary disease.

Must not have a hematocrit less than 30 or research blood withdraw greater than 450 mL in the previous six weeks.

Must not be pregnant.

Must not have a history of angina or known coronary artery disease, because these patients are at risk for exacerbation during the vasopressin test.

The SF-36 questionnaire will only be given to individuals who speak and read English fluently. Patients may participate in the remainder of the study, however, if they do not meet this criterion.

Eligible Sex

ALL

Accepts Healthy Volunteers

No